Replies to post #216587 on Biotech Values

[DewDiligence]

PTLA—The author of the iVillage message you posted is drowning in details that ultimately won’t matter much from business standpoint, IMO.

Eliquis, Xarelto, and Pradaxa are well-entrenched in the marketplace. Yes, Bevyxxa can capture some market share, but it will costly to do so in terms of either PTLA’s internal SG&A spending or PTLA’s ceding a big chunk of the Bevyxxa economics to a partner.

Bottom line: Bevyxxa can be a decent-selling drug, but it won’t be the mega-blockbuster that some people seem in your milieu seem to be expecting.

[DewDiligence]

PTLA—(-10%/AH)—CHMP likely to reject Bextrixaban MAA:

https://finance.yahoo.com/news/portola-pharmaceuticals-announces-results-chmp-214747588.html

As a consolation prize, the CHMP will probably approve Andexanet Alfa (the FXa antidote).

As I've presviously posted on multiple occasions, PTLA was lucky to get FDA approval of Bevyxxa (the US brand name for betrixaban) based on a single phase-3 trial with a not-so-impressive p-value. The CHMP is quite reasonable to say no, IMO.

[DewDiligence]

PTLA—2Q18 Bevyxxa sales=$33K (not a typo). I think the skepticism expressed in #msg-137659892 has been borne out.